Eastern Bank’s Neurocrine Biosciences NBIX Stock Holding History

Eastern Bank’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-191	Closed	-$26.8K	–	1219
2025 Q3	$26.8K	Buy	+191	New	+$25.9K	﹤0.01%	672

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Eastern Bank's NBIX Position: Q4 2025 in Review

Eastern Bank sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 191 shares — an estimated $26.8K sold.

Eastern Bank first reported a position in NBIX in Q3 2025 and held it in 1 quarter. The position peaked at $26.8K in Q3 2025. 733 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

Eastern Bank reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
Eastern Bank sold 191 Neurocrine Biosciences shares in Q4 2025, an estimated $26.8K.
Eastern Bank first reported a position in Neurocrine Biosciences in Q3 2025 and held it in 1 quarter.
Eastern Bank's Neurocrine Biosciences position peaked at $26.8K in Q3 2025.
733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Eastern Bank's 13F filing for Q4 2025, filed 14 Jan 2026.